Molecular Imaging

Catch up on the most-well viewed radiology content in August 2025.

Catch up on the most-well viewed prostate imaging content in August 2025.

Catch up on the top radiology content of the past week.

Catch up on the top radiology content of the past week.

In addition to facilitating centralized scanning for a variety of imaging, the TechLive system may help ease the strain of technologist shortages and broaden access to advanced imaging exams.

Combining sub-second load times and AI-automated features, the PET/CT Viewer Mode and Mammography Viewer Mode may help address bottlenecks in nuclear medicine imaging and mammography workflows.

Catch up on the top radiology content of the past week.

An analysis of over 749,000 Medicare beneficiaries diagnosed with prostate cancer over a five-year period found that Black men were 13 percent less likely to receive PET imaging and 16 percent less likely to receive MRI in comparison to White men.

Catch up on the most-well viewed radiology content in July 2025.

Catch up on the top radiology content of the past week.

In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.

Stay updated with the latest in radiology, including PET, MRI, and AI research, plus essential insights on mammography and cardiac imaging.

Currently in a phase I trial for solid prostate cancer tumors, the deoxycytidine kinase inhibitor TRE-515 garnered the fast track designation for possible combination use with Pluvicto in treating mCRPC.

The HCPCS level II code A9616 goes into effect on October 1 for the PSMA PET preparation kit, which received FDA approval in March.

For patients with amyloid β (Aβ)-positive findings on positron emission tomography, higher educational attainment was associated with accelerated accumulation and spread of tau, according to new research.

Catch up on the top radiology content of the past week.

Catch up on the most-well viewed radiology content in June 2025.

Expanded indications for the flutemetamol F18 injection include amyloid quantification and monitoring of anti-amyloid treatments.

The additional indication for the preparation kit of gallium Ga-68 gozetotide may facilitate earlier use of PSMA-targeted treatment for men with prostate cancer.

Catch up on the top radiology content of the past week.

For people with mild cognitive impairment (MCI), new research suggests that a combination of amyloid-positive and tau-positive PET findings is linked to a nearly 70 percent risk of progressing to dementia in five years in comparison to an approximate 30 percent risk for those with amyloid β positive and tau-negative PET.

Catch up on the top radiology content of the past week.

For patients with gastric cancer, (68Ga)Ga-FAPI-04 PET offered double the sensitivity for lymph node metastases in comparison to (18F)FDG PET.

Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.

Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.

The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.

Catch up on the top radiology content of the past week.

Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.